Ascletis Pharma Slides 7.4% as Sagimet’s Phase 3 Acne Trial Could Spark New Growth
Ascletis Pharma’s stock dips 7.4%, but a new U.S. Phase 3 trial for denifanstat could spark a comeback, offering a first once‑daily oral acne therapy.
3 minutes to read
